Landscape and function of multiple mutations within individual oncogenes
- 8 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 582 (7810), 95-99
- https://doi.org/10.1038/s41586-020-2175-2
Abstract
Sporadic reports have described cancer cases in which multiple driver mutations (MMs) occur in the same oncogene1,2. However, the overall landscape and relevance of MMs remain elusive. Here we carried out a pan-cancer analysis of 60,954 cancer samples, and identified 14 pan-cancer and 6 cancer-type-specific oncogenes in which MMs occur more frequently than expected: 9% of samples with at least one mutation in these genes harboured MMs. In various oncogenes, MMs are preferentially present in cis and show markedly different mutational patterns compared with single mutations in terms of type (missense mutations versus in-frame indels), position and amino-acid substitution, suggesting a cis-acting effect on mutational selection. MMs show an overrepresentation of functionally weak, infrequent mutations, which confer enhanced oncogenicity in combination. Cells with MMs in the PIK3CA and NOTCH1 genes exhibit stronger dependencies on the mutated genes themselves, enhanced downstream signalling activation and/or greater sensitivity to inhibitory drugs than those with single mutations. Together oncogenic MMs are a relatively common driver event, providing the underlying mechanism for clonal selection of suboptimal mutations that are individually rare but collectively account for a substantial proportion of oncogenic mutations.This publication has 45 references indexed in Scilit:
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013
- Cancer Genome LandscapesScience, 2013
- Lessons from the Cancer GenomeCell, 2013
- The genetic landscape of high-risk neuroblastomaNature Genetics, 2013
- Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor CellsPLOS ONE, 2009
- Deletion ofIKZF1and Prognosis in Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 2009
- Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal TumorsJournal of Clinical Oncology, 2006
- EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2005
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2005
- Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic LeukemiaScience, 2004